Skip to main content
Supplementary Figure 2 | Arthritis Research & Therapy

Supplementary Figure 2

From: Successful immunotherapy with matrix metalloproteinase-derived peptides in adjuvant arthritis depends on the timing of peptide administration

Supplementary Figure 2

Binding affinity of matrix metalloproteinase (MMP) peptides to purified RT1.BL. The binding affinity of the competitor peptides (MMP peptides) was tested in a competitive MHC class II peptide binding assay in a dose range of 0–256 μM. * IC50, concentration of competitor peptide (μM) resulting in 50% inhibition of the binding of marker peptide to RT1.BL, as evaluated by Molecular Analyst Software (see Supplementary Materials and methods).

Back to article page